Catalyst Biosciences Drops On Study Halt
The appearance of neutralizing antibodies to Catalyst's investigational subcutaneous Factor IX product sent the company's share price southwards.
You may also be interested in...
2021 saw a record number of novel drug launches and the size of the pipeline topped 20,000 candidates for the first time, new analysis shows, while China came of age as a pharma player.
Ahead of the American Society of Clinical Oncology meeting in early June, analysts at Biomedtracker have highlighted select high-impact late-breaking abstracts that are due to presented, including therapies from AbbVie, Gilead Sciences, Pfizer, Takeda, Amgen, AstraZeneca and Daiichi Sankyo.
2021 was another record-breaking year for novel product launches as COVID-19 continued to make an impact, but the industry’s response to the pandemic did not fully account for the acceleration seen in this strict measure of R&D productivity.